Floatz logo

ad5 cea vaccine

Colorectal Neoplasm

National Cancer Institute (NCI)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

117 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

ad5 cea vaccine is also rated in:

Lynch syndromeDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
lung cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →